Core Viewpoint - The article highlights the diverse applications of silk, particularly in biomedical fields, showcasing its potential in wound healing and artificial cornea production, driven by the unique properties of silk proteins [10][12][13]. Group 1: Applications of Silk - Silk proteins can be used to create gentle dressings that accelerate healing without causing allergies [13] - An artificial cornea made from silk proteins can be rapidly transplanted to restore vision for patients with severe corneal damage [10][13] - The biocompatibility and biodegradability of silk make it a promising material for regenerative medicine, including cartilage, skin, and corneal tissue repair [12][13] Group 2: Genetic Research and Development - The establishment of a "silkworm gene bank" has preserved over 1,200 genetic resources, covering more than 90% of known genetic variations in silkworms [16][17] - The completion of the "thousand silkworm genome" project has created a comprehensive genetic dictionary, allowing for precise identification of genes that control silk properties [17] - Genetic editing techniques are being utilized to produce silkworms that can yield silk with specific desired traits, significantly reducing the time required for breeding [17] Group 3: Longevity and Regeneration Insights - Research has identified a key gene, OSER1, in silkworms that is associated with longevity, which may provide insights into human aging and disease [19][20] - The regenerative mechanisms observed in silkworms could offer new approaches for treating degenerative diseases and injury repair [20]

Core Viewpoint - The collaboration between Four Seasons Pharmaceutical and Deep Origin Biopharmaceuticals marks a significant step in the application of AI technology in the medical aesthetics sector, focusing on innovative product development and strategic positioning in the "AI + Medical Aesthetics" innovation track [1][2] Group 1: Collaboration Details - Four Seasons Pharmaceutical has signed a framework agreement with Deep Origin Biopharmaceuticals to establish an AI research and development company, aiming to explore AI-driven new medical aesthetic product development [1] - The partnership will leverage over 20 years of industry resources, commercialization pipelines, and R&D reserves from Four Seasons, while Deep Origin will provide its proprietary protein design automation platform and core technologies [1] Group 2: Technological Advancements - The collaboration aims to create a "dry-wet closed-loop" R&D platform that integrates AI design, high-throughput experimental validation, and data feedback iteration, enhancing the value of the medical aesthetics business [2] - The use of advanced generative models and large language models will shorten the early-stage R&D molecular screening cycle, reduce development costs, and improve the success rate of R&D in the medical aesthetics field [2] Group 3: Market Positioning - The focus on high-end medical aesthetic raw material innovation aims to break the dependency on imported high-end materials, promoting the upgrade of Four Seasons' medical aesthetic products towards "high-end and domestically produced" [1] - The collaboration is expected to address unmet market needs in the medical aesthetics sector, injecting momentum into the long-term development of Four Seasons' medical aesthetics business and enhancing its core competitiveness and market value [2]